United Therapeutics Corporation UTHR
At closeNov 3, 2026, 7:58 PM EST
After hours · Nov 3, 7:58 PM ET
- YTD
- +23.41%
- 1 year
- +37.08%
- Market cap
- 25.79B
- Revenue (ttm)
- 3.15B
- Profit margin
- 41.56%
- EPS (ttm)
- 27.92
- Shares out
- 42.89M
- P/E ratio
- 21.54
- Forward P/E
- 17.75
- YTD return
- +23.41%
- 1-year return
- +37.08%
- Volume
- 611.88K
- Avg volume
- 716.14K
- Open
- 596.14
- Previous close
- 596.13
- Day's range
- 596.14 – 606.16
- 52-week range
- 430.02 – 609.99
- Beta
- 0.48
- Analysts
- Buy
- Price target
- 670.93 (+11.6%)
- Earnings date
- Nov 4, 2026
1m +0.90 (+0.15%)
Key statistics
- Enterprise value
- 22.91B
- PEG ratio
- 2.22
- Price / sales
- 8.18
- Price / book
- 4.01
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -1.90%
- Free cash flow
- 557.14M
- Total cash
- 2.66B
- Total debt
- 0
- Return on equity
- 19.31%
- Short % of float
- 6.69%
- 50-day average
- 528.76
- 200-day average
- 532.16
Analyst view
Consensus: buy
- Target (low)
- 368.00
- Target (mean)
- 670.93
- Target (high)
- 850.00
- Strong buy3
- Buy8
- Hold3
- Sell1
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 6.34.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 6.01 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 6.86 | 7.27 | +0.41 | +5.98% |
| May 6, 2026 | Mar 31, 2026 | 7.00 | 5.82 | -1.18 | -16.86% |
| Feb 25, 2026 | Dec 31, 2025 | 7.13 | 7.70 | +0.57 | +7.99% |
| Oct 29, 2025 | Sep 30, 2025 | 6.89 | 7.16 | +0.27 | +3.92% |
| Jul 30, 2025 | Jun 30, 2025 | 7.29 | 6.41 | -0.88 | -12.07% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 22, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 19, 2026 | Leerink Partners | main | Outperform | Outperform |
| Oct 8, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 7, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Oct 1, 2026 | BTIG | up | Neutral | Buy |
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- unither.com
News
ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test 
SpaceX Launch Customer Varda Says a Single Flight Could Help Make Medicine for Millions 
SGIOY vs. UTHR: Which Stock Is the Better Value Option? 
JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $695 
Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for 
$100 Invested In United Therapeutics 15 Years Ago Would Be Worth This Much Today 
United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension 
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock 
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $697 
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Your note
Sign in to keep a note on UTHR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENKOWITZ MICHAEL | President | Conversion of Exercise of derivative security | Mar 12, 2026 | 0 |
| CAUSEY CHRISTOPHER | Director | Sale | Mar 29, 2026 | 4,190 |
| EDGEMOND JAMES C. | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 21, 2026 | 18,876 |
| GILTNER RICHARD A | Director | Conversion of Exercise of derivative security | Jul 8, 2026 | 21,884 |
| KURZWEIL RAYMOND C | Director | Conversion of Exercise of derivative security | Jul 8, 2026 | 13,320 |
| MAHON PAUL A | General Counsel | Sale | Sep 30, 2026 | 45,172 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.34% | 5,294,529 | 3.18B | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 6.48% | 2,777,777 | 1.67B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.48% | 1,919,429 | 1.15B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.47% | 1,918,256 | 1.15B | Jun 29, 2026 |
| State Street Corporation | 4.43% | 1,898,064 | 1.14B | Jun 29, 2026 |
| Renaissance Technologies, LLC | 3.98% | 1,708,739 | 1.03B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 1,527,799 | 918.70M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.14% | 1,347,720 | 810.41M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.27% | 973,490 | 585.38M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.68% | 719,385 | 432.58M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.13% | 486,555 | 292.58M | Jun 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.75% | 323,432 | 194.49M | Sep 29, 2026 |